Nav: Home

IGC scientists discover a tap that controls the flow of pro-inflammatory molecules

July 26, 2018

One of the major therapeutic targets for inflammatory diseases is the inflammation-inducing molecule TNF. However, excess levels of TNF cause side effects and can lead to diseases. In a study now published in the eLIFE journal*, the research team led by Colin Adrain of the Gulbenkian Institute of Science (IGC, Portugal) discovered a new protein, called iTAP, that controls the levels of TNF in circulation by regulating its release from immune cells. These findings open avenues for the design of improved therapeutics for inflammatory diseases.

TNF is released from the surface of immune cells called macrophages in response to infection and helps to coordinate the actions of the immune system to fight the pathogen. Although beneficial in clearing infection, excess or prolonged TNF release can be harmful. Elevated levels of TNF are associated with septic shock, can drive the development of some cancers, and are strongly associated with chronic inflammatory diseases (e.g. rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, ankylosing spondylitis).

Specific therapies that block the actions of TNF are in clinical use, but are not always effective on their own, and patients sometimes stop responding to the drugs during the course of treatment. A better understanding of the machinery that controls TNF release from cells is important to identify new strategies to treat inflammatory diseases.

"For some years now, we have focused on identifying the molecular pathways involved in TNF secretion. TNF molecules are normally attached to the cell surface, but to perform many of their functions, they have to be released from the membrane by an enzyme called TACE. Now we have found a new part of the machinery called iTAP, whose role is to prolong the amount of time TACE spends on the cell surface to promote TNF release", says Colin Adrain, leader of the IGC Membrane Traffic Laboratory and lead author of this study.

The researchers found that when the iTAP gene is removed from human or mouse cells, the release of TNF is reduced substantially, because TACE is destabilized on the cell surface and degraded in lysosomes, the cell's garbage disposal unit.

"If we think of iTAP as a tap that controls TNF release into circulation, controlling iTAP through a drug may enable partially closing the TNF tap in a patient with an inflammatory disease. This may help reduce harmful inflammatory responses without impeding the TNF functions necessary for the normal functioning of the body", explains Ioanna Oikonomidi, a PhD student at IGC and the first author of the article. But the IGC team warns that "more research and validation is needed before this discovery can translate into clinical advances."
-end-
This research was conducted at the Gulbenkian Institute of Science in collaboration with researchers from the Trinity College Dublin (Ireland), the Institute of Genetics and Molecular Medicine of the Edinburgh Cancer Research UK Center (Edinburgh, UK), the Center for Biological Systems Analysis (ZBSA) of the Albert Ludwigs University (Freiburg, Germany), the Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic (Prague, Czech Republic) and the Institut fu?r Analytische Chemie of the University of Vienna (Vienna, Austria).

This study was funded by Worldwide Cancer Research, Fundação para a Ciência e a Tecnologia (FCT, Portugal), Science Foundation Ireland, the Ministry of Education, Youth and Sports of the Czech Republic, and the German Research Council.

* Oikonomidi, I. et al. iTAP, a novel iRhom interactor, controls TNF secretion by policing the stability of iRhom/TACE. eLife 2018;7:e35032 (doi: 10.7554/eLife.35032) https://elifesciences.org/articles/35032

Instituto Gulbenkian de Ciencia

Related Immune Cells Articles:

Nutrient deficiency in tumor cells attracts cells that suppress the immune system
A study led by IDIBELL researchers and published this week in the American journal PNAS shows that, by depriving tumor cells of glucose, they release a large number of signaling molecules.
Experience matters for immune cells
The discovery that immune T cells have a spectrum of responsiveness could shed light on how our immune system responds to infections and cancer, and what goes wrong in immune diseases.
Immune cells against Alzheimer's?
German researchers have developed a novel, experimental approach against Alzheimer's.
Arming the body's immune cells
Researchers at UC have discovered a previously unknown mechanism that could explain the reason behind decreased immune function in cancer patients and could be a new therapeutic target for immunotherapy for those with head and neck cancers.
Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.
How an immune system regulator shifts the balance of immune cells
Researchers have provided new insight on the role of cyclic AMP (cAMP) in regulating the immune response.
How the immune system becomes blind to cancer cells
Researchers have described the activation of a key protein used by tumor cells to stop the body's immune response.
What protects killer immune cells from harming themselves?
White blood cells, which release a toxic potion of proteins to kill cancerous and virus-infected cells, are protected from any harm by the physical properties of their cell envelopes, find scientists from UCL and the Peter MacCallum Cancer Centre in Melbourne.
How self-reactive immune cells are allowed to develop
A research team at Lund University in Sweden has found the mechanism that controls the growth of B1-cells in mice.
Identification of new populations of immune cells in the lungs
In an article published in Nature Communications, the Immunophysiology Laboratory of the GIGA Institute, headed by Prof.
More Immune Cells News and Immune Cells Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.